Refresh publishes Florida guide comparing Botox, Dysport, Xeomin and Daxxify

Refresh - Aesthetics & Wellness has released a patient guide that compares the major neuromodulator brands, explains FDA-approved uses and outlines when dermal filler may be the better option. The Florida practice says the guide is meant to help patients navigate a fast-growing injectable market and make safer, more individualized treatment decisions.

Why it matters: - Injectable treatments remain the dominant category in nonsurgical aesthetics, and patients are increasingly comparing brands, prices and duration before booking. - The guide aims to reduce confusion around neuromodulators and steer patients toward treatment choices based on anatomy, goals and safety rather than online trends. - The comparison also arrives as regulators continue to scrutinize unapproved botulinum toxin products sold online.

What happened: - Refresh - Aesthetics & Wellness released a new patient-focused guide comparing Botox, Dysport, Xeomin and Daxxify. - The physician-led practice has nine locations across Florida. - Christopher Senger, M.D., chief medical officer of Refresh - Aesthetics & Wellness, said the best injectable is the one selected for the patient’s anatomy, history, goals and safety by a qualified medical provider. - The guide addresses a common patient question: which neuromodulator is best.

The details: - Botox, Dysport, Xeomin and Daxxify are prescription botulinum toxin type A products, but they are not interchangeable. - The products differ in formulation, dosing units, FDA-approved indications and supporting clinical data. - Product choice can depend on facial anatomy, muscle activity, treatment history, desired movement, previous response and the area being treated. - The International Society of Aesthetic Plastic Surgery reported in its 2025 Global Survey that botulinum toxin remained the most common nonsurgical aesthetic procedure worldwide, with about 7.3 million procedures performed by plastic surgeons. - Hyaluronic acid filler ranked second, with about 4.7 million procedures. - Botox Cosmetic, or onabotulinumtoxinA, is FDA approved for moderate to severe glabellar lines, crow’s feet, forehead lines and platysma bands in appropriate adult patients. - Dysport, or abobotulinumtoxinA, is FDA approved in the U.S. for temporary improvement of moderate to severe glabellar lines in adults younger than 65. - Xeomin, or incobotulinumtoxinA, contains the active neurotoxin without the accessory complexing proteins found in some other formulations. - Xeomin’s U.S. labeling includes temporary improvement of moderate to severe glabellar lines, horizontal forehead lines and lateral canthal lines in adults. - Daxxify, or daxibotulinumtoxinA-lanm, is a peptide-formulated neuromodulator FDA approved cosmetically for temporary improvement of moderate to severe glabellar lines in adults. - In clinical research supporting Daxxify, more than half of treated subjects still had none or mild glabellar lines at six months based on investigator and patient assessments. - Duration still varies by patient, dose, anatomy and treatment area. - Units for Botox, Dysport, Xeomin and Daxxify are product specific and cannot be converted 1-to-1. - A lower per-unit price on one product does not automatically mean the treatment costs less overall. - Neuromodulators and dermal fillers solve different problems: neuromodulators reduce muscle movement, while fillers address volume, contour and certain folds or static lines. - Refresh offers the Juvéderm Collection and RHA Collection, and says product selection should follow anatomical assessment rather than trend. - Refresh is LegitScript Certified and offers Botox, Dysport, Xeomin, Daxxify, dermal fillers, advanced laser treatments, skin rejuvenation and physician-directed wellness services. - The practice operates in Jupiter, Wellington, Port St. Lucie, Vero Beach, Fort Lauderdale, Tampa, Brandon, Palm Harbor and St. Petersburg. - Refresh says patients should know the exact product being injected, whether it is FDA approved, who is performing the injection, what license that provider holds, what areas are being treated, and the risks, alternatives and expected duration.

Between the lines: - The guide is as much about consumer education as product comparison. - Refresh is pushing back on the idea that a popular brand, a lower unit price or a longer-lasting result can be generalized across all patients. - The practice is also reinforcing a broader safety message: cosmetic injectables should be selected and administered by licensed medical providers, not by social-media shorthand or price alone.

What's next: - Refresh is encouraging patients to schedule evaluations with licensed providers to review anatomy, treatment history and aesthetic goals. - The practice says it will continue offering multiple neuromodulators and filler families so providers can match treatment to the patient rather than relying on a single product. - Patients can find more information at the practice’s website.

The bottom line: - Refresh’s new guide makes one core argument: the best injectable is the one chosen for the right patient, in the right area, for the right reason.